Literature DB >> 28509079

"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy.

Sina Jasim1, Mark A Nathan2, Keith C Bible2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28509079     DOI: 10.1007/s12020-017-1321-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.

Authors:  Christos Sachpekidis; Lionel Larribere; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss; Jessica C Hassel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-31       Impact factor: 9.236

2.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

3.  Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Authors:  Sied Kebir; Rolf Fimmers; Norbert Galldiks; Niklas Schäfer; Frederic Mack; Christina Schaub; Moritz Stuplich; Michael Niessen; Theophilos Tzaridis; Matthias Simon; Gabriele Stoffels; Karl-Josef Langen; Björn Scheffler; Martin Glas; Ulrich Herrlinger
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531

  3 in total
  1 in total

Review 1.  Bone metastases in thyroid cancer.

Authors:  Nicole M Iñiguez-Ariza; Keith C Bible; Bart L Clarke
Journal:  J Bone Oncol       Date:  2020-02-19       Impact factor: 4.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.